InfuSystem (INFU) Stock: Buy, Sell, or Hold?
INFU - InfuSystem Holdings, Inc.
$12.15
0.03 (0.25%)
▲
5d:
-0.25%
30d:
-0.74%
90d:
+34.25%
HOLD
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When INFU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INFU is fairly valued with market pricing in 3.7% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: INFU is fairly valued with market pricing in 3.7% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$21.19
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$13.16
7.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INFU is currently trading at $12.15, which is considered fair relative to its 30-day fair value range of $12.02 to $12.32. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.4) compared to its historical average (19.2). At these levels, the market is pricing in 3.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INFU is in a strong uptrend. The price is currently testing key support at $11.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $16.83 (+38.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INFU is in a strong uptrend. The price is currently testing key support at $11.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 52/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $16.83 (+38.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$12.02 -
$12.32
Company Quality Score
58/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
78.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 16th percentile)
- NEUTRAL: Mixed technical signals (52/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.5% below Wall St target ($16.83)
- NEUTRAL: Market pricing in 3.7% annual earnings growth - fairly valued
- NEUTRAL: Bottoming setup forming (52/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$12.02 -
$12.32
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.85
(7.0%)
Support & Resistance Levels
Support Level
$11.81
Resistance Level
$12.47
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.44
Wall Street Target
$16.83
(+38.5%)
Revenue Growth (YoY)
2.6%
Earnings Growth (YoY)
25.0%
Profit Margin
6.0%
Valuation Premium vs History
+3.7% premium
PE vs Historical
21.4 vs 19.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.7%
(market-implied from PE analysis)
1-Year Target
$12.60
(+4%)
2-Year Target
$13.07
(+8%)
3-Year Target
$13.55
(+12%)
3-Yr Target (if PE normalizes)
(PE: 21→19)
PE COMPRESSION
$12.13
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.4, Growth: 32.8%)
$28.46
(+134%)
Base:
(SPY PE: 20.2, Growth: 32.8%)
$26.78
(+120%)
Bear:
(PE: 17.1, Growth: 32.8%)
$22.76
(+87%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 30.30 | Current EPS (TTM): $0.40
Bull Case
$18.89
(+56%)
Analyst growth 41.7%, PE expands to 33.3
Base Case
$17.17
(+41%)
Market implied 41.7%, PE stable at 30.3
Bear Case
$8.24
(-32%)
Severe decline -20.0%, PE contracts to 25.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 5:03 AM ET
Data refreshes hourly during market hours. Next update: 6:03 AM
Data refreshes hourly during market hours. Next update: 6:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INFU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
